MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting and Mount Sinai Winter Dermatology Symposium

NEW YORK & IRVINGTON, N.Y.--(BUSINESS WIRE)--MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist feedback from its second Clinical Advisory Meeting held in conjunction with the 16th Annual Mount Sinai Winter Dermatology Symposium last week. The symposium weekend kicked off with a Clinical Advisory Meeting featuring ten leading dermatologists, specializing in melanoma and pigmented skin lesions, who participated in a roundtable discussion about MelaFind which was moderated by Dr. Gary Goldenberg. He and Dr. Julie Russak led the meeting with...